Genzyme Files Complaint Against Sarepta Concerning Gene Therapy Elevidys®
JD Supra Law
AUGUST 9, 2024
On July 26, 2024, Genzyme filed a complaint (“Complaint”) against Sarepta Therapeutics (“Sarepta”) in the District of Delaware. Genzyme Corp. v. Sarepta Therapeutics, Inc., No. 1:24-cv-00882 (D. Del.). In its complaint, Genzyme alleges that Sarepta infringed Genzyme’s U.S. Patent Nos. 7,704,721 and 9,051,542 (collectively, “the Patents-In-Suit”) by making, using, offering for sale, and/or selling Elevidys® (delandistrogene moxeparvovec-rokl) in the U.S.
Let's personalize your content